UAE Approves First Oral Drug for Progressive Multiple Sclerosis

Photo:WAM

The United Arab Emirates has marked a historic moment in the field of global healthcare with the approval of Tolebrutinib, the first oral medicine in the world designed to treat non-relapsing secondary progressive multiple sclerosis (SPMS). This development is being celebrated as a groundbreaking achievement, both for patients battling this challenging disease and for the UAE’s growing reputation as a leader in medical innovation.

A Global First – Why This Approval Matters

Multiple sclerosis (MS) is a chronic neurological disease that affects the central nervous system, including the brain and spinal cord. Patients with MS often suffer from symptoms such as fatigue, muscle weakness, difficulty in walking, and problems with balance or vision. Over time, many patients enter a stage known as secondary progressive MS (SPMS).

In SPMS, disability keeps worsening even if the patient no longer experiences frequent relapses. Until now, treatments mostly focused on controlling relapses, but no approved medicine existed that directly targeted disability progression itself.

This is where Tolebrutinib becomes a revolutionary step. By approving it, the UAE has positioned itself at the forefront of medical progress, ensuring patients gain access to a treatment that could change the course of their lives.

What is Tolebrutinib and How Does It Work?

Tolebrutinib is an oral pill – making it far easier for patients compared to traditional injections or IV therapies. But what makes it truly unique is the way it works inside the body.

* The drug directly targets B cells and microglia – special immune cells that cause long-term inflammation inside the brain and spinal cord.

* These cells are believed to be one of the main reasons behind the gradual worsening of disability in MS patients.

* By calming down this hidden inflammation, Tolebrutinib slows down the build-up of permanent nerve damage.

This makes the drug the first therapy that addresses disability progression independent of relapses – something no other MS treatment has achieved so far.

Stay informed with the latest news. Follow DXB News Network on WhatsApp Channel 

Backed by Strong Science

The approval of Tolebrutinib was not taken lightly. It was based on scientific evidence collected through extensive research carried out in partnership with the National Multiple Sclerosis Society.

The studies showed that Tolebrutinib:

* Can slow disability progression in patients who have entered the SPMS stage.

* Provides protection against long-term nerve damage.

* Improves patients’ quality of life, allowing them to stay independent for longer.

This evidence-based approach reflects the UAE’s commitment to global standards in healthcare, where every approval is supported by strong scientific proof.

UAE’s Vision for Healthcare Leadership

The Emirates Drug Establishment emphasized that this achievement reflects the UAE’s forward-looking regulatory policies. Unlike many countries where drug approvals can take years, the UAE has created a flexible, fast, and science-driven system that ensures patients receive advanced treatments without unnecessary delays.

Dr. Fatima Al Kaabi, Director-General of the Establishment, highlighted the significance of the approval. She explained:

“The approval of Tolebrutinib marks a transformative step in addressing one of the most complex neurological diseases. It embodies our commitment to accelerating access to innovative therapies that make a real difference in patients’ lives.”

She further added that this success is the result of international cooperation and a clear national vision to make the UAE a hub for medical innovation.

Impact on Patients and Families

For people living with SPMS, the news brings hope and relief. Patients often describe the progressive stage of the disease as the most frustrating, as disability increases despite no new relapses. Many slowly lose independence, making it difficult to walk, use their hands, or perform simple daily activities.

Tolebrutinib represents more than just a pill – it is a chance for patients to:

* Slow the decline in physical ability.

* Maintain their independence for longer.

* Live with greater dignity and less reliance on others.

For families, it means less emotional and financial stress, as their loved ones can enjoy an improved quality of life.

International Collaboration and Innovation

This milestone is also an example of how the UAE works hand in hand with global organizations to bring the best science to its people. The partnership with the National Multiple Sclerosis Society demonstrates the country’s dedication to evidence-based decision-making.

By being the first nation in the world to approve this therapy, the UAE shows that it is ready to adopt global innovations and transform them into real benefits for patients at home.

Strengthening UAE’s Global Position

This approval is not only important for patients but also for the UAE’s reputation as a healthcare leader in the region and the world. It shows that the country can:

* Fast-track medical innovations in areas of urgent need.

* Maintain strict standards of safety and effectiveness.

* Act as a role model for other nations looking to modernize their healthcare systems.

It is part of a broader vision where the UAE aims to be a center for scientific research, innovation, and advanced medicine, attracting global partnerships and investments in healthcare.

The approval of Tolebrutinib in the UAE is more than just a medical announcement – it is a turning point in the fight against multiple sclerosis. For patients, it brings new hope and independence. For doctors, it opens a new chapter in neurological care. And for the UAE, it cements its role as a pioneer in medical innovation on the global stage.

With this bold step, the UAE proves that it is not only keeping pace with scientific advancements but is also leading the way in bringing them to patients faster than ever before.

#Dubai breaking news today #Dubai latest updates #UAE NEWS #Voices of UAE feature #Voices of UAE #Breaking News